Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Fox Factory Holding Corp. Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds AlloVir, Inc. Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amplitude, Inc. Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Palo Alto Networks, Inc. Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds British American Tobacco p.l.c. Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Mobileye Global Inc. Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Cummins Inc. Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds BioNTech SE Investors of Upcoming Deadline
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Dada Nexus Limited Investors of Upcoming Deadline
-
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
-
AGF Appoints Laura Dottori-Attanasio, an Accomplished Leader in the Business Community, to Board of Directors
-
Vital Farms Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
Bitfarms Reports Fourth Quarter and Full Year 2023 Results
-
Reykjavík Energy Consolidated Annual Financial Statements 2023 | Progress in Climate and Energy Affairs
-
Altisource Announces Fourth Quarter and Full Year 2023 Financial Results
-
KP Tissue declares a Quarterly Dividend of $0.18 per Common Share
-
OTC Markets Group Upgrades Three Grayscale Products to OTCQX
-
KP Tissue Releases Fourth Quarter and Full Year 2023 Financial Results
-
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
-
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
-
Methode Electronics, Inc. Reports Fiscal 2024 Third Quarter Financial Results
-
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
-
Oomnitza Research Reveals that Almost 50% of Enterprises Face Considerable Increase in Audit Expenditures and Delays Due to Poor Technology Inventory Data
-
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $8 Million
-
Interface Opens New Headquarters in St Louis, MO
-
Astec Announces Chief Financial Officer Transition
-
Xunlei Limited Schedules 2023 Unaudited Fourth Quarter and Fiscal Year Earnings Release on March 14, 2024
-
LexinFintech Holdings Ltd. to Report Fourth Quarter and Full Year 2023 Unaudited Financial Results on March 20, 2024
-
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
-
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
-
Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call
-
AirSculpt Technologies Announces Participation at BofA Securities Consumer and Retail Conference
-
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
-
Manitoba Harvest Hemp Foods Introduces Protein-Rich Breakfast Staples With New Superseed Instant Oatmeal
-
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
-
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Maplebear Inc. Investors of Upcoming Deadline
-
Municipality Finance Group’s Annual Report for 2023 published
-
Siili Solutions Plc - Managers' transactions - Salo
-
Siili Solutions Plc - Managers' transactions - Pienimäki
-
Siili Solutions Plc - Managers' transactions - Lindfors
-
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
-
ABM Reports First Quarter Fiscal 2024 Results and Raises Outlook for Fiscal Year 2024 Adjusted EPS
-
Dimensional Fund Advisors Ltd. : Form 8.3 - WINCANTON PLC - Ordinary Shares
-
TransUnion to Present at the 2024 BofA Securities Information Services Conference
-
Dimensional Fund Advisors Ltd. : Form 8.3 - TRITAX BIG BOX REIT PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRENT COMMUNICATIONS PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Redrow plc - Ordinary Shares
